![](/img/cover-not-exists.png)
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
Arkenau, H.- T., Plummer, R., Molife, L. R., Olmos, D., Yap, T. A., Squires, M., Lewis, S., Lock, V., Yule, M., Lyons, J., Calvert, H., Judson, I.Volume:
23
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdr451
Date:
May, 2012
File:
PDF, 492 KB
english, 2012